JERSEY CITY, N.J., April 08, 2024--Organon To Report First Quarter 2024 Results and Host Conference Call on May 2, 2024
SHANGHAI, China & JERSEY CITY, N.J., April 08, 2024--Organon and Henlius announce that Phase 3 Comparative Clinical Study of Prolia® and Xgeva® (denosumab) Biosimilar Candidate HLX14 Met Primary Endpoint
JERSEY CITY, N.J., February 20, 2024--Organon Announces HADLIMA Has Been Exclusively Selected by the US Department of Veterans Affairs (VA), Replacing HUMIRA on Its National Formulary